Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Activity of MK0518 (Raltegravir) in ART-Naive HIV Patients
NCT00100048Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2005
- Primary completion
- Oct 2006
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of raltegravir in human immunodeficiency virus infection (HIV), sponsored by Merck & Co.. Started Jan 2005; status: completed.
02
Drugs
raltegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00100048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00100048.